MedTrace Logo

Comparison of Dequalinium Chloride (Fluomizin) vs Oral Metronidazole for the Treatment of Bacterial Vaginosis

NCT05788991 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 151

Last updated 2024-10-16

Study results available
· View outcomes & findings →

Summary

The goal of this clinical trial is to show the efficacy and safety of dequalinium chloride in the treatment of bacterial vaginosis compared to metronidazole.

Conditions

  • Bacterial Vaginosis
  • Vaginal Infection
  • Vaginal Diseases

Interventions

DRUG

Dequalinium Chloride

Fluomizin vaginal tablets (10 mg dequalinium chloride) used once a day for 6 days

DRUG

Metronidazole Oral

Metronidazole oral tablets (500 mg) taken twice a day for 7 days

Sponsors & Collaborators

  • Medinova AG

    lead INDUSTRY

Principal Investigators

  • Philipp Grob, PhD · Medinova AG

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-26
Primary Completion
2022-08-25
Completion
2022-08-25

Countries

  • Czechia
  • Poland
  • Slovakia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05788991 on ClinicalTrials.gov